IgM antibodies were consistently detected across APS phenotypes, yet their clinical significance remains controversial, particularly after their exclusion as stand-alone criteria in the 2023 ACR/EULAR classification. This evidence concerns the gene CD40LG and autoimmune polyendocrinopathy.